Experience the Quality With Free AOCNP Exam Questions That Helps Candidates Pass

Anti-CD20 therapies deplete B cells and blunt humoral responses, reducing vaccine efficacy for months. When possible, complete inactivated vaccines at least 2–4 weeks before starting therapy to allow an immune response. During treatment, inactivated vaccines (e.g., influenza) may be given but responses are suboptimal; revaccination or booster strategies may be needed after immune reconstitution. Live vaccines are contraindicated during and for a period after anti-CD20 therapy due to risk of vaccine-related infection. Most guidelines recommend deferring routine vaccinations until ≥6 months—often up to 12 months—after the last rituximab dose to improve serologic responses, individualized by counts and clinical status. Declaring vaccines “unnecessary” (Option D) ignores preventable morbidity. The APRN reviews immunization history, prioritizes influenza annually and pneumococcal/COVID-19 per current schedules, coordinates timing around treatment cycles, and educates on household “cocooning.” Document plans in the EHR and revisit post-therapy to update titers/boosters, optimizing protection while balancing oncologic timelines.

Opioid-induced constipation (OIC) is predictable and should be prevented. First-line prophylaxis is a stimulant laxative (senna or bisacodyl), with or without a stool softener; titrate to 1–2 soft BMs/day. If inadequate, add an osmotic agent (polyethylene glycol, lactulose, magnesium hydroxide as renal function allows). Bulk-forming fiber (Option A) can worsen bloating and is ineffective in slowed-transit OIC. Antidiarrheals (Option C) are contraindicated. For persistent OIC despite optimized oral regimens, peripherally acting µ-opioid receptor antagonists (PAMORAs) like naloxegol, naldemedine, or methylnaltrexone can rapidly restore bowel function without reversing central analgesia; assess for GI obstruction risk before use. Abruptly stopping opioids (Option D) is unsafe and undermines pain control. APRNs should provide written bowel plans at opioid initiation, assess for red flags (obstruction, severe abdominal pain), encourage mobility and hydration as tolerated, and review interacting medications (anticholinergics). Document regimen effectiveness and adjust proactively during titration of analgesics.

Febrile neutropenia is an oncologic emergency requiring prompt empiric, broad-spectrum anti-pseudomonal coverage within one hour of presentation. Key steps include immediate blood cultures (both peripheral and from central line lumens if present) and initiation of an anti-pseudomonal β-lactam such as cefepime, piperacillin–tazobactam, or meropenem. The presence of a tender, erythematous port site raises concern for catheter-related bloodstream infection and potential MRSA involvement, warranting the addition of vancomycin at presentation. Waiting for culture results (Option C) delays time-to-antibiotic, which correlates with higher mortality. Oral therapy (Option A) is inappropriate in a hemodynamically tachycardic patient with a suspected line infection. Delaying therapy for imaging (Option D) also violates time-critical standards. Risk stratification (e.g., MASCC or CISNE) guides disposition, but initial parenteral therapy is standard for high-risk features such as profound neutropenia (ANC <500), suspected line infection, and recent induction chemotherapy. Ongoing management includes daily reassessment, source control if needed, and de-escalation based on cultures and clinical response.

Financial toxicity affects adherence, quality of life, and outcomes. After an initial positive screen, best practice is structured assessment with a validated instrument such as the COmprehensive Score for financial Toxicity (COST) to identify specific drivers—copays, travel, lost wages. APRNs should immediately engage financial navigation and social work to pursue manufacturer patient-assistance programs, foundation grants, transportation resources, and benefits optimization (disability, FMLA). Medication access strategies may include 340B pharmacies, generic substitutions, dose-banding when clinically appropriate, and prior-authorization support. Documenting the plan in the EHR, setting check-ins aligned with treatment cycles, and tracking adherence refills help prevent silent nonadherence. Reassurance alone (Option A) ignores modifiable barriers. A single voucher (Option C) provides short-term relief but fails to address ongoing needs or sustainable solutions. Advising patients to stop therapy (Option D) without exploring alternatives contravenes patient-centered care. Incorporating financial outcomes into quality metrics and providing culturally sensitive education (health literacy, digital access) further reduce disparities and support equitable oncology care.

Low-dose CT (LDCT) lung screening targets adults at sufficiently high ongoing risk. Eligibility commonly includes a defined age range, pack-year threshold, and current smoking or cessation within the past 15 years. Individuals who exceed the quit-time window (>15 years) or age out of the program should generally discontinue screening if they have no new risk factors or symptoms and would not pursue curative treatment if detected. Chest X-ray (Option C) has no mortality benefit in screening. Extending screening indefinitely (Option A) dilutes benefit-harm balance by increasing false positives, radiation exposure, and anxiety. Changing to every 3 years (Option D) is not evidence-based. The APRN’s role is to confirm personal risk factors, ensure documentation of prior screening history, engage in shared decision-making about stopping, emphasize smoking abstinence relapse prevention, and pivot to other age-appropriate preventive services (vaccinations, colorectal and abdominal aortic aneurysm screening where indicated) and symptom awareness with a clear return pathway for new respiratory complaints.